drug
POMALIDOMIDE
Marketedupdated 6mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(5)
approval · 5
Trials studying POMALIDOMIDE
- phase2A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- phase1A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
- phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 14, 2027
175 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Jun 21, 2031compositionUS 88284274.6y
- Jun 21, 2031compositionUS 88284274.6y
- Jun 21, 2031compositionUS 88284274.6y
- Jun 21, 2031compositionUS 88284274.6y
- Nov 19, 2030patentUS 10555939*PED4.0y
- Nov 19, 2030patentUS 10555939*PED4.0y
- Nov 19, 2030patentUS 10555939*PED4.0y
- Nov 19, 2030patentUS 10555939*PED4.0y
- Nov 19, 2030patentUS 9993467*PED4.0y
- Nov 19, 2030patentUS 9993467*PED4.0y
- Nov 19, 2030patentUS 9993467*PED4.0y
- Nov 19, 2030patentUS 9993467*PED4.0y
- May 19, 2030formulationUS 105559393.5y
- May 19, 2030formulationUS 105559393.5y
- May 19, 2030formulationUS 105559393.5y
- May 19, 2030formulationUS 105559393.5y
- May 19, 2030formulationUS 99934673.5y
- May 19, 2030formulationUS 99934673.5y
- May 19, 2030formulationUS 99934673.5y
- May 19, 2030formulationUS 99934673.5y
FDA exclusivities (16)
- Nov 14, 2027PEDPediatric (6mo bonus)359d
- Nov 14, 2027PEDPediatric (6mo bonus)359d
- Nov 14, 2027PEDPediatric (6mo bonus)359d
- Nov 14, 2027PEDPediatric (6mo bonus)359d
- May 14, 2027ODE-296Orphan Drug (7y)175d
- May 14, 2027ODE-297Orphan Drug (7y)175d
- May 14, 2027ODE-296Orphan Drug (7y)175d
- May 14, 2027ODE-297Orphan Drug (7y)175d
- May 14, 2027ODE-296Orphan Drug (7y)175d
- May 14, 2027ODE-297Orphan Drug (7y)175d
- May 14, 2027ODE-296Orphan Drug (7y)175d
- May 14, 2027ODE-297Orphan Drug (7y)175d
- Aug 30, 2026PCPC
- Aug 30, 2026PCPC
- Aug 30, 2026PCPC
- Aug 30, 2026PCPC
News(1)
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that